• J Buon · Apr 2014

    The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation?

    • Qi Liu, Aimin Li, Shufang Sun, Rongcheng Luo, and Fengsheng Chen.
    • Cancer Center of Southern Medical University, Guangzhou, Guangdong, China.
    • J Buon. 2014 Apr 1; 19 (2): 398-405.

    PurposeModified Response Evaluation Criteria In Solid Tumors (mRECIST), developed by the American Association for the Study of Liver Diseases (AASLD) criteria measure changes in arterialized hepatocellular carcinoma (HCC) and aim at providing a common framework for the design of clinical trials. It still isn't determined whether mRECIST can be applied in routine clinical practice and whether mRECIST could estimate viable tumor correctly.MethodsWe retrospectively analyzed data from patients subjected to transcatheter arterial chemoembolization (TACE) as initial treatment for advanced HCC in our institution. Not suitable for using mRECIST standard cases and the agreement in response between RECIST and mRECIST were assessed. Then we selected HCC patients who achieved complete response (CR) according to mRECIST, following PET-CT examinations. We also compared arterial enhanced computed tomography (CT) or magnetic resonance imaging (MRI) with positron emission tomography (PET)-CT examination and analyzed their correlation.ResultsOut of 143 HCC patients, mRECIST evaluation appeared to be applicable for 128 (89.51%) assessable patients. In these 128 assessable patients, the objective response (OR) rates (complete/CR+partial response/PR) according to RECIST and mRECIST were 64.06% (82 of 128 patients) and 78.13% (100 of 128; p<0.001), respectively. Discordance in the response evaluations between the two methods was observed in 46 patients (35.94%) and was statistically significant (Kappa=0.491; p<0.001). The overall survival (OS) of patients who achieved an OR as assessed by mRECIST or by RECIST was significantly better than the survival of non-responding patients (stable disease/SD, or progressive disease/PD).ConclusionsAlthough mRECIST criteria show a good correlation with prognosis, they demand strict requirements for patient selection and couldn't be useful as a tool for routine clinical practice. Furthermore, merely by means of contrast-enhanced CT or MRI, mRECIST couldn't estimate viable tumor sufficiently.

      Pubmed     Free full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…